Ocrelizumab似乎可以减少多发性硬化症的复发和残疾，但证据质量是中等的。

{"title":"Ocrelizumab似乎可以减少多发性硬化症的复发和残疾，但证据质量是中等的。","authors":"Graziella Filippini","doi":"10.1136/ebmed-2017-110721","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":12182,"journal":{"name":"Evidence-Based Medicine","volume":" ","pages":"215-216"},"PeriodicalIF":0.0000,"publicationDate":"2017-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Ocrelizumab appears to reduce relapse and disability in multiple sclerosis but quality of evidence is moderate.\",\"authors\":\"Graziella Filippini\",\"doi\":\"10.1136/ebmed-2017-110721\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":12182,\"journal\":{\"name\":\"Evidence-Based Medicine\",\"volume\":\" \",\"pages\":\"215-216\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Evidence-Based Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/ebmed-2017-110721\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2017/11/8 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Evidence-Based Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/ebmed-2017-110721","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2017/11/8 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}